International Conference on Hematology and Hemoglobinopathies
IC2H
Official Invitation Letter Available
An official invitation letter will be provided upon successful registration for your participation in the conference.
Benefits of Registering as Listener
Access to All Conference Sessions
Plenary, keynote and parallel sessions
Networking Opportunities
Connect with global educators & researchers
Certificate of Participation
Digital certificate of participation
Invitation Letter Support
Official invitation letter after successful registration
Conference Kit / Digital Materials
E-proceedings & resource materials
Access to Keynote Sessions
Learn from leading experts & scholars
Conference Session Tracks
Aligned with UN Sustainable Development Goals
The conference's session tracks effectively support the following SDGs.
This track focuses on the latest innovations in molecular diagnostic techniques for the identification of hemoglobinopathies. Emphasis will be placed on the integration of genomic technologies and their impact on patient outcomes.
SDG 3
SDG 9
This session will explore strategies for enhancing patient care in hematology, including shared decision-making and personalized treatment plans. Discussions will highlight the importance of patient engagement and education in managing hematological disorders.
SDG 3
SDG 10
This track will examine contemporary practices in transfusion therapy, including indications, safety protocols, and emerging technologies. Participants will discuss the challenges and advancements in ensuring optimal transfusion outcomes for patients.
SDG 3
SDG 9
This session will showcase groundbreaking clinical research studies that are shaping the future of hematology. Presentations will cover novel therapeutic approaches and their implications for clinical practice.
SDG 3
SDG 9
This track will delve into the latest laboratory techniques employed in the diagnosis of hematological disorders. Participants will gain insights into the role of automation and new technologies in enhancing diagnostic accuracy.
SDG 3
SDG 4
This session will focus on the identification and validation of biomarkers in hematological diseases, exploring their potential role in guiding therapy. The discussions will highlight the translational aspects of biomarker research.
SDG 3
SDG 9
This track will address the bridge between basic research and clinical application in the context of hemoglobinopathies. Emphasis will be placed on how translational research can inform treatment strategies and improve patient outcomes.
SDG 3
SDG 9
This session will investigate the underlying mechanisms of various hematological disorders, including genetic and environmental factors. Participants will discuss how these insights can inform therapeutic approaches.
SDG 3
SDG 4
This track will highlight novel therapeutic agents and strategies being developed for the treatment of hemoglobinopathies. Discussions will include clinical trial results and the potential for new treatment paradigms.
SDG 3
SDG 9
This session will explore the ethical challenges associated with conducting research in hematology, particularly in vulnerable populations. Participants will engage in discussions about informed consent, data privacy, and equitable access to therapies.
SDG 3
SDG 10
This track will provide a platform for discussing global health challenges related to hematology and hemoglobinopathies. Participants will share insights on disparities in care and strategies for improving access to treatment worldwide.
SDG 3
SDG 10